Avivit Peer

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Dean F. Bajorin, J. Alfred Witjes, Jürgen E. Gschwend et al. · New England Journal of Medicine · 2021 · 1K citations · Full text

Medicine, Oncology, Surgery +17

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2023 · 319 citations · Full text

Medicine, Oncology, Urology +17